Search

Your search keyword '"Montes Moreno S"' showing total 151 results

Search Constraints

Start Over You searched for: Author "Montes Moreno S" Remove constraint Author: "Montes Moreno S" Database MEDLINE Remove constraint Database: MEDLINE
151 results on '"Montes Moreno S"'

Search Results

1. Castleman disease-type histopathological patterns of lymph nodes in patients with plasma cell neoplasia and POEMS syndrome.

2. Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma.

Catalog

Books, media, physical & digital resources

3. Is Bone Marrow Trephine Biopsy Necessary in Multiple Myeloma Patients at Diagnosis?

4. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.

5. Intramuscular hemangioma of the infraspinatus muscle: a rare presentation.

6. DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma.

7. Osteomesopyknosis associated with a novel ALOX5 variant that impacts the RANKL pathway.

8. From Castleman disease histopathological features to idiopathic multicentric Castleman disease: a multiparametric approach to exclude potential iMCD histopathological mimickers.

9. Kikuchi-Fujimoto disease type lymph node reaction with increased plasmacytoid dendritic cells may appear as a side effect following COVID-19 vaccination: Report of a case and literature review.

10. Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.

11. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.

12. CTNNB1 somatic mutations drive Wnt pathway activation in a case of incidental intranodal palisaded myofibroblastoma.

13. Correction: "The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms" Leukemia. 2022 Jul;36(7):1720-1748.

14. Systemic Mastocytosis with Associated Hematological Neoplasms. Diagnostic features and unique response pattern to tyrosine kinase inhibitors and allo-bone marrow transplantation therapy.

15. Expert consensus on the integrated diagnosis of idiopathic multicentric Castleman disease.

16. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

17. Mycosis fungoides: A rare cause of giant cardiac mass.

18. An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy.

19. CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma.

20. BCL2 translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival.

21. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma.

22. ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer.

23. Pathological fracture from clinically occult breast cancer.

24. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.

25. Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.

26. Prognostic factors, therapeutic approaches, and distinct immunobiologic features in patients with primary mediastinal large B-cell lymphoma on long-term follow-up.

27. The clinico-pathological spectrum of primary cutaneous lymphoma other than mycosis fungoides/Sezary syndrome.

28. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.

29. Correction to: Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.

30. Update on lymphoproliferative disorders of the gastrointestinal tract: disease spectrum from indolent lymphoproliferations to aggressive lymphomas.

31. The broad and challenging landscape of extranodal lymphoproliferations.

32. High-mobility group box (TOX) antibody a useful tool for the identification of B and T cell subpopulations.

33. MYD88L265P mutated IgA lymphoplasmacytic lymphoma.

34. DUSP22 -rearranged anaplastic lymphomas are characterized by specific morphological features and a lack of cytotoxic and JAK/STAT surrogate markers.

35. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.

36. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.

37. Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era.

38. Spontaneously Ruptured Spleen Samples in Patients With Infectious Mononucleosis: Analysis of Histology and Lymphoid Subpopulations.

39. Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma.

40. A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group.

41. Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.

42. Castleman Disease and Rosai-Dorfman Disease.

43. In situ neoplasia in lymph node pathology.

44. Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocations.

46. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.

47. p-MAPK1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients.

48. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1.

49. RelA NF-κB subunit activation as a therapeutic target in diffuse large B-cell lymphoma.

50. Angioimmunoblastic T-cell lymphoma with a clonal plasma cell proliferation that underwent immunoglobulin isotype switch in the skin, coinciding with cutaneous disease progression.